Entrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Estimates By $0.69 EPS

Entrada Therapeutics (NASDAQ:TRDA) issued its quarterly earnings results on Thursday. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.69, Zacks reports. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%.

Entrada Therapeutics Trading Down 0.1 %

TRDA stock traded down $0.02 during trading hours on Thursday, hitting $12.00. 79,355 shares of the stock traded hands, compared to its average volume of 112,624. The stock has a 50-day simple moving average of $14.40 and a 200 day simple moving average of $16.26. Entrada Therapeutics has a one year low of $11.35 and a one year high of $21.79. The company has a market cap of $449.19 million, a P/E ratio of 7.55 and a beta of -0.17.

Insider Activity at Entrada Therapeutics

In related news, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $20.77, for a total value of $476,359.95. Following the completion of the transaction, the insider now owns 4,402,849 shares in the company, valued at $91,447,173.73. This trade represents a 0.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Kory James Wentworth sold 5,000 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $20.00, for a total value of $100,000.00. Following the completion of the transaction, the chief financial officer now owns 73,849 shares of the company’s stock, valued at $1,476,980. This trade represents a 6.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,935 shares of company stock valued at $596,330 over the last 90 days. 7.59% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on TRDA shares. Roth Mkm started coverage on Entrada Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $29.00 price target on the stock. Roth Capital raised Entrada Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Tuesday. Finally, Oppenheimer raised their price target on Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 6th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.